|Bid||3.6300 x 1800|
|Ask||3.6400 x 1800|
|Day's Range||3.5276 - 3.6325|
|52 Week Range||1.5400 - 6.1900|
|Beta (3Y Monthly)||2.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Agenus Inc. shot up 60% in premarket trade Thursday after the company announced it was partnering with Gilead Sciences Inc. to develop up to five immuno-oncology therapies. Under the deal, Agenus will receive $150 million upon closing, including a $120 million upfront cash payment and $30 million in equities. Agenus will also receive up to about $1.7 billion in potential future fees and milestones. Gilead, whose shares ticked up 0.3% in premarket trade after the announcement, will receive exclusive rights to one of Agenus' investigational therapies and options to license two others. Gilead will also have the right of first negotiation for two additional undisclosed pre-clinical programs. Shares of Agenus have fallen 38% in the year to date, while shares of Gilead have fallen 10%. The S&P 500 has fallen 6% in the year to date.
Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies. Agenus will get an upfront cash payment of $120 ...
Agenus (AGEN) delivered earnings and revenue surprises of -16.00% and 18.98%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Lexington, Massachusetts-based company said it had a loss of 29 cents per share. The biotechnology company posted revenue of $12.8 million in the period. The company's shares closed at $1.88. A year ...
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anyone researching Agenus Inc (NASDAQ:AGEN) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. InvestorsRead More...
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.